Optimer®: Accelerating your journey to clinic
Speeding project timelines can be vital to the development of any life science product. Optimer offers an antibody alternative that can cut as much 75% (2.8 years) off the time to clinic, compared to standard antibodies, helping you bring diagnostic and therapeutic solutions to market faster.
Find out how Optimer compare to antibodies, to deliver:
- A faster path to clinic
- A simpler path to clinic with less room for error
- A more consistent product for less waste in the product lifecycle
- The ability to pursue new targets for novel diagnostics and therapeutics
- Low immunogenic molecules for optimal therapeutic profiles
- High quality, non-animal derived reagents for adherence to directive 2010/63/EU
Download the whitepaper to find out how you could cut valuable years from discovery and development with Optimer.